Descripción del proyecto
Mejorar la seguridad de los medicamentos
Los acontecimientos nocivos asociados con determinados medicamentos se conocen como reacciones adversas y podrían estar relacionados con la dosis o el momento de administración, o ser el resultado de la retirada o el fracaso de un tratamiento. El proyecto MEDIKURA, financiado con fondos europeos, ha desarrollado una infraestructura digital para recopilar y analizar datos de reacciones adversas con el fin de mejorar la seguridad de los medicamentos. Pacientes, médicos y empresas farmacéuticas pueden acceder a la plataforma en la nube, que constituye un método transparente y centralizado para informar de reacciones adversas. Se espera que, a largo plazo, la plataforma acelere el descubrimiento de medicamentos basado en datos y minimice las reacciones adversas.
Objetivo
The mission of MEDIKURA is to digitize drug safety: our process innovation helps pharma companies to capture, enrich, and analyze drug-related data provided by patients and doctors. We address the societal problem that more than 200,000 European citizens die from Adverse Drug Reactions (ADRs, colloquially referred to as drug side-effects) every year, whereas less than 1% of ADR cases are officially reported by patients and doctors. To improve drug safety, the new EU regulation ICH E2B(R3) came into effect in late 2017 - as a result, pharma companies are subject to increasing cost and time pressure in ADR monitoring.
Our solution is to build the digital infrastructure for ADR data – to improve drug safety, enable more targeted therapies, and accelerate data-driven drug discovery. We streamline the process of capturing, enriching, and analyzing ADR data through a cloud-based platform that connects pharma companies with patients and doctors. Our goal is to replace the decentralized, analogue drug safety process with a transparent, centralized, and digital system. The resulting value proposition to pharma companies is three-fold. In terms of time savings, we reduce the timespan to close a ADR case and report it to public authorities by more than 50%. In terms of money, we can save processing cost of more than 50% per ADR case and reduce liability risk significantly. In terms of data quality, we provide comprehensive information through a digital backchannel to both patients and doctors that allows to enrich drug-related data and prepare it for subsequent analyses.
Ámbito científico
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicinepharmacology and pharmacydrug safety
- medical and health scienceshealth sciencespersonalized medicine
- natural sciencescomputer and information sciencesdata sciencedata exchange
- medical and health sciencesbasic medicinepharmacology and pharmacyadverse drug reactions
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEInst-2018-2020-1
Régimen de financiación
SME-1 - SME instrument phase 1Coordinador
80335 MUNCHEN
Alemania
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.